Novel nanoparticulate drug delivery systems.
Ralf P Friedrich, Marina Pöttler, Iwona Cicha, Stefan Lyer, Christina Janko, Christoph Alexiou
Author Information
- Ralf P Friedrich: ENT-Department, Section of Experimental Oncology & Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship for Nanomedicine, University Hospital Erlangen, Glueckstr. 10a, 91054 Erlangen, Germany.
- Marina Pöttler: ENT-Department, Section of Experimental Oncology & Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship for Nanomedicine, University Hospital Erlangen, Glueckstr. 10a, 91054 Erlangen, Germany.
- Iwona Cicha: ENT-Department, Section of Experimental Oncology & Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship for Nanomedicine, University Hospital Erlangen, Glueckstr. 10a, 91054 Erlangen, Germany.
- Stefan Lyer: ENT-Department, Section of Experimental Oncology & Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship for Nanomedicine, University Hospital Erlangen, Glueckstr. 10a, 91054 Erlangen, Germany.
- Christina Janko: ENT-Department, Section of Experimental Oncology & Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship for Nanomedicine, University Hospital Erlangen, Glueckstr. 10a, 91054 Erlangen, Germany.
- Christoph Alexiou: ENT-Department, Section of Experimental Oncology & Nanomedicine (SEON), Else Kröner-Fresenius-Stiftung-Professorship for Nanomedicine, University Hospital Erlangen, Glueckstr. 10a, 91054 Erlangen, Germany.
No abstract text available.
Alzheimer Disease
Animals
Blood Platelets
Cell Membrane
Delayed-Action Preparations
Drug Delivery Systems
G(M1) Ganglioside
Humans
Magnets
Nanoparticles
Neoplasms
Neutrophils
Delayed-Action Preparations
G(M1) Ganglioside
